Jon, Aducanumab and the two Eisai drugs have been in the trials pipeline for some time and Biogen has only had a good look at 2-73 in their lab in the last six months. As i said, if Sigma 1 shows some competitive efficacy that will drive where the company decide to spend money on their future AZ efforts.
The new CEO Vounatsos said he was looking to revitalize Biogen's pipeline. So far he hasn't spent nearly as much cash as the 2013 $3.25B Tysabri deal with Elan. Competition in the M/S field where Biogen has been king is driving Biogen's management to bolster their pipeline. Their SP has gone from the low $400 to around $250 today. As I posted a short time ago, Micheal Ehler, the new head of R&D, has said that the company will be "acquiring drugs before they've been completely proven."
None of this proves that there are serious negotiations in progress but it does provide some clues. Who's to say the the good Doctor is not talking to others to heat up competition. "The Art of the Deal"
News 
Market Data 
Discover 
